Seneca Biopharma, Inc. (SNCA)
| Market Cap | 18.16M |
| Revenue (ttm) | 13,520 |
| Net Income (ttm) | -13.89M |
| Shares Out | 17.31M |
| EPS (ttm) | -0.21 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 5 |
| Last Price | $1.19 |
| Previous Close | $1.11 |
| Change ($) | 0.08 |
| Change (%) | 7.21% |
| Day's Open | 1.09 |
| Day's Range | 1.05 - 1.20 |
| Day's Volume | 2,200,607 |
| 52-Week Range | 0.50 - 2.20 |
GERMANTOWN, Md., Jan. 20, 2021 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need...
Regeneron Pharmaceuticals (NASDAQ: REGN) shares are trading higher after the company announced an additional U.S. order to purchase 1.25 million doses of its COVID-19 antibody cocktail bringin...
NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Buildingin New...
NEW YORK, Dec. 18, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Seneca Biopharma, Inc. (NASDAQ: SNCA) and its board of directors concerning the ...
NEW YORK, Dec. 17, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Seneca Biopharma, Inc. ("Sene...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Seneca Biopharma, Inc. (NASDAQ: SNCA) and Leading BioSciences, Inc. is fa...
GERMANTOWN, Md., Dec. 15, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need...
GERMANTOWN, Md., Aug. 13, 2020 /PRNewswire/ -- Seneca Biopharma, Inc.
GERMANTOWN, Md., May 22, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need,...
GERMANTOWN, Md., May 22, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq:SNCA), a clinical-stage biopharmaceutical company developing novel treatments for various diseases of high unmet me...
GERMANTOWN, Md., May 15, 2020 /PRNewswire/ -- Seneca Biopharma, Inc. (Nasdaq: SNCA), a biopharmaceutical company focused on developing novel treatments for diseases of high unmet medical need,...
About SNCA
Seneca Biopharma, a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidates include NSI-189, a chemical entity, which has been complet... [Read more...]
| Industry Biotechnology | Founded 1996 |
| CEO Kenneth Carter | Employees 7 |
| Stock Exchange NASDAQ | Ticker Symbol SNCA |
Financial Performance
In 2019, SNCA's revenue was $15,394, a decrease of -94.08% compared to the previous year's $260,000. Losses were -$8.35 million, 69.6% more than in 2018.